methyl 3,5-N,N,N',N'-tetramethylaminobenzoate | 21903-30-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 3,5-N,N,N',N'-tetramethylaminobenzoate
• 英文别名: methyl 3,5-bis(dimethylamino)benzoate
• CAS: 21903-30-0
• 化学式: C₁₂H₁₈N₂O₂
• 分子量: 222.287
• InChiKey: NAOZURCTVHQPDK-UHFFFAOYSA-N

物化性质

• 沸点：
  347.9±37.0 °C(Predicted)
• 密度：
  1.093±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 3,5-N,N,N',N'-tetramethylaminobenzoate 在 lithium aluminium tetrahydride 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 生成 2-[3,5-Bis(dimethylamino)phenyl]acetonitrile
  参考文献：
  名称：

  Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors

  摘要：

  The inhibition of tyrosine kinase-mediated signal transduction pathways represents a therapeutic approach to the intervention of proliferative diseases such as cancer, atherosclerosis, and restenosis. A novel series of pyrido[2,3-d]pyrimidine inhibitors of the PDGFr, bFGFr, and c-Src tyrosine kinases was developed from compound library screening and lead optimization.(1) In addition, highly selective inhibitors of the FGFr tyrosine kinase were also discovered and developed from this novel series of pyrido[2,3-d]pyrimidines. The syntheses, biological evaluation, and structure-activity relationships of this series are reported. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00445-9
• 作为产物：
  描述：

  聚合甲醛 、 3,5-二硝基苯甲酸甲酯 生成 methyl 3,5-N,N,N',N'-tetramethylaminobenzoate
  参考文献：
  名称：

  Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors

  摘要：

  The inhibition of tyrosine kinase-mediated signal transduction pathways represents a therapeutic approach to the intervention of proliferative diseases such as cancer, atherosclerosis, and restenosis. A novel series of pyrido[2,3-d]pyrimidine inhibitors of the PDGFr, bFGFr, and c-Src tyrosine kinases was developed from compound library screening and lead optimization.(1) In addition, highly selective inhibitors of the FGFr tyrosine kinase were also discovered and developed from this novel series of pyrido[2,3-d]pyrimidines. The syntheses, biological evaluation, and structure-activity relationships of this series are reported. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00445-9

文献信息

• Benzylpyrimidines
  申请人：Hoffmann-La Roche Inc.

  公开号：US04039543A1

  公开（公告）日：1977-08-02

  Benzylpyrimidines of the formula ##STR1## wherein R.sup.1 and R.sup.2 each, independently, is amino, optionally C.sub.1.sub.-3 -alkyl-substituted pyrrolo, pyrrolidino, piperidino, -NHR.sup.3, -N(R.sup.3).sub.2, -NHR.sup.4, -N(R.sup.3)(R.sup.4),-NR.sup.3 COOR.sup.3, -NHCOOR.sup.3, -NHCONHR.sup.3, -NHCONH.sub.2 or -N(NO)R.sup.3 or wherein R.sup.3 is C.sub.1.sub.-4 -alkyl or C.sub.2.sub.-4 -alkenyl, R.sup.4 is acyl; Z is hydrogen, chlorine, bromine, pyrrolo, pyrrolidino, piperidino or morpholino or R.sup.3, OR.sup.3 or -N(R.sup.3).sub.2 ; A is an oxygen atom bonded to one of the cyclic nitrogen atoms; and n is 0 or 1 are prepared. The benzylpyrimidines are useful as potentiators of the activity of the sulfonamides.

  公式##STR1##中的苄基嘧啶，其中R.sup.1和R.sup.2分别独立地是氨基，可选择性地是C.sub.1.sub.-3-烷基取代的吡咯，吡咯啉，哌啶，-NHR.sup.3，-N(R.sup.3).sub.2，-NHR.sup.4，-N(R.sup.3)(R.sup.4)，-NR.sup.3 COOR.sup.3，-NHCOOR.sup.3，-NHCONHR.sup.3，-NHCONH.sub.2或-N(NO)R.sup.3，其中R.sup.3是C.sub.1.sub.-4-烷基或C.sub.2.sub.-4-烯基，R.sup.4是酰基；Z是氢，氯，溴，吡咯，吡咯啉，哌啶或吗啉或R.sup.3，OR.sup.3或-N(R.sup.3).sub.2；A是与其中一个环氮原子键合的氧原子；n为0或1。制备苄基嘧啶，这些苄基嘧啶可用作磺胺类药物活性的增强剂。
• Synthesis of Aryl-Substituted 1,3-Butadiones
  作者：Burkhard König

  DOI：10.1081/scc-120016361

  日期：2003.1.4

  The synthesis of several electron donor substituted 1-aryl-1,3-butadiones and their use as ligands in the formation of scandium(III) complexes is reported.
• US4039543A
  申请人：——

  公开号：US4039543A

  公开（公告）日：1977-08-02
• US4251454A
  申请人：——

  公开号：US4251454A

  公开（公告）日：1981-02-17
• Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors
  作者：Cleo J.C. Connolly、James M. Hamby、Mel C. Schroeder、Mark Barvian、Gina H. Lu、Robert L. Panek、Aneesa Amar、Cindy Shen、Alan J. Kraker、David W. Fry、Wayne D. Klohs、Annette M. Doherty

  DOI：10.1016/s0960-894x(97)00445-9

  日期：1997.9

  The inhibition of tyrosine kinase-mediated signal transduction pathways represents a therapeutic approach to the intervention of proliferative diseases such as cancer, atherosclerosis, and restenosis. A novel series of pyrido[2,3-d]pyrimidine inhibitors of the PDGFr, bFGFr, and c-Src tyrosine kinases was developed from compound library screening and lead optimization.(1) In addition, highly selective inhibitors of the FGFr tyrosine kinase were also discovered and developed from this novel series of pyrido[2,3-d]pyrimidines. The syntheses, biological evaluation, and structure-activity relationships of this series are reported. (C) 1997 Elsevier Science Ltd.